Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
3 studies found for:    insmed | Open Studies
Show Display Options
Rank Status Study
1 Recruiting Extension Study of Arikace™ in CF Patients With Chronic Pseudomonas Aeruginosa Infection
Condition: Cystic Fibrosis
Intervention: Drug: Liposomal amikacin for inhalation
2 Unknown  Study to Evaluate Arikace™ in CF Patients With Chronic Infection Due to Pseudomonas Aeruginosa
Condition: Cystic Fibrosis
Interventions: Drug: Liposomal amikacin for inhalation;   Drug: Placebo for liposomal amikacin for inhalation
3 Recruiting Arikace® for Nontuberculous Mycobacteria
Condition: Pulmonary Nontuberculous Mycobacterial Lung Disease
Interventions: Drug: Liposomal amikacin for inhalation;   Drug: placebo

Indicates status has not been verified in more than two years